Solid forms of anti-EGFR antibodies

Details Solid forms of anti-EGFR antibodies Solid forms of anti-EGFR antibodies

2011-06-14

2011-06-14

Noakes, Suzanne M. (Department: 1656)

Chemistry: natural resins or derivatives; peptides or proteins;

Proteins, i.e., more than 100 amino acid residues

Blood proteins or globulins, e.g., proteoglycans, platelet...

C530S388100

Reexamination Certificate

active

07960516

ABSTRACT:
The invention relates to solid forms of antibodies against the EGF receptor, in particular precipitates and crystals of monoclonal antibodies against the EGF receptor, particularly preferably of Mab C225 (cetuximab) and Mab h425 (EMD 72000), which result in biologically active antibody protein through dissolution or suspension in aqueous medium, obtainable by precipitation of the antibody and/or one of its variants and/or fragments dissolved or suspended in aqueous medium by means of a precipitation reagent. The invention furthermore relates to pharmaceutical preparations comprising at least one solid form of above-mentioned antibodies in precipitated non-crystalline, precipitated crystalline or in soluble or suspended form, and optionally excipients and/or adjuvants and/or further pharmaceutical active ingredients, and to a process for the preparation of solid forms of anti-EGFR antibodies according to the invention.

REFERENCES:
patent: 5558864 (1996-09-01), Bendig et al.
patent: 6217866 (2001-04-01), Schlessinger et al.
patent: 2002/0136719 (2002-09-01), Shenoy et al.
patent: 2002/0197261 (2002-12-01), Li et al.
patent: 2004/0006212 (2004-01-01), Goldstein et al.
patent: 2004/0170632 (2004-09-01), Mahler et al.
patent: WO 2006/009694 (2006-01-01), None
Weber, Overview of Crystallization Methods. Methods in Enzymology, 1997, vol. 276, pp. 13-22.
Drenth, “Principles of Protein X-Ray Crystallography”, 2nd Edition, 1999 Springer-Verlag New York Inc., Chapter 1, p. 1-21.
McPherson, A. Current Approaches to Macromolecular Crystallization. European Journal of Biochemistry. 1990. vol. 189, pp. 1-23.
ATCC Index of publically available deposited Hybridoma Cell Lines. Dec. 17, 2008. http://www.atcc.org/Portals/1/Pdf/CellCatalog/Hybridomas.pdf.
Ahamed et al. Phase Behaviour of Intact Monoclonal Antibody. Biochemical Journal, Jul. 2007, vol. 93, pp. 610-619.
Kundrot, C.E. Which Strategy for a Protein Crystallization Project? Cellular Molecular Life Science. 2004. vol. 61, pp. 525-536.
Benevenuti et al., Crystallization of Soluble Proteins in Vapor Diffusion for X-ray Crystallography, Nature Protocols, published on-line Jun. 28, 2007, 2(7):1633-1651.
Cudney R. Protein Crystallization and Dumb Luck. The Rigaku Journal. 1999. vol. 16, No. 1, pp. 1-7.
Baselga J: “The EGFR as a Target for Anticancer Therapy-Focus on Cetuximab” European Journal of Cancer, Pergamon Press, Oxford, GB, Bd. 37, Sep. 2001, pp. 16-22, XP004307911; ISSN: 0959-8049.
Abou-Jawde Rony et al: “An Overview of Targeted Treatments in Cancer” Clinical Therapeutics, Bd. 25, Nr. 8, Aug. 2003, pp. 2121-2137, XP002316108; ISSN: 0149-2918.
Hurrell J.G.R.: “Monoclonal Hybridoma Antibodies: Techniques and Applications” 1982, CRC Press, Boca Raton, Florida, XP009043454; p. 51.
Deutscher M.P.: “Guide to Protein Purification” 1990, Academic Press, San Diego, XP002316109, pp. 285-306.

Affiliated with

Also associated with

Rating

Solid forms of anti-EGFR antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Solid forms of anti-EGFR antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Solid forms of anti-EGFR antibodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2672001